Kanazawa University Research Reveals Origin of Lung Cancer Drug Resistance
The findings demonstrated what causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib.
Read MorePosted by Chaunie Brusie | Apr 13, 2019 | Research |
The findings demonstrated what causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib.
Read MorePosted by Chaunie Brusie | Apr 6, 2019 | Research |
Individuals identified with VeriStrat poor results had significantly lower overall survival when treated with immune checkpoint inhibitor-based regimens.
Read MorePosted by Steve Halasey | Jan 31, 2019 | Lung Cancer |
The companies’ collaboration underscores the need for proteomic data to enable precision medicine strategies for lung cancer patients.
Read MorePosted by Steve Halasey | Dec 12, 2018 | Research |
The serum proteomic test could optimize treatment by identifying patients unlikely to benefit from immunotherapy.
Read MorePosted by Melissa Mayer | Oct 26, 2018 | Lung Cancer |
New kit examines most relevant EGFR exons that affect therapeutic decisions for lung cancer patients.
Read More